The FDA issued draft guidance that, when finalized, will provide the agency’s perspective on the ethical considerations for including and protecting children in clinical trials and will assist industry, sponsors and IRBs when considering the enrollment of children.
Read more: New FDA Draft Guidance Aims to Protect Children who Participate in Clinical Trials